loading
Coherus Oncology Inc stock is traded at $1.23, with a volume of 2.57M. It is up +8.85% in the last 24 hours and up +33.36% over the past month. Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
See More
Previous Close:
$1.13
Open:
$1.14
24h Volume:
2.57M
Relative Volume:
2.01
Market Cap:
$95.45M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.4731
EPS:
-2.6
Net Cash Flow:
$-175.17M
1W Performance:
+17.14%
1M Performance:
+33.36%
6M Performance:
+14.95%
1Y Performance:
-6.82%
1-Day Range:
Value
$1.13
$1.24
1-Week Range:
Value
$1.03
$1.24
52-Week Range:
Value
$0.6603
$2.43

Coherus Oncology Inc Stock (CHRS) Company Profile

Name
Name
Coherus Oncology Inc
Name
Phone
(650) 649-3530
Name
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Name
Employee
177
Name
Twitter
@coherus_bio
Name
Next Earnings Date
2025-03-10
Name
Latest SEC Filings
Name
CHRS's Discussions on Twitter

Compare CHRS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CHRS
Coherus Oncology Inc
1.23 124.36M 257.24M -237.89M -175.17M -2.60
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-16-24 Downgrade UBS Buy → Neutral
Nov-17-23 Initiated Robert W. Baird Outperform
Nov-08-23 Downgrade Maxim Group Buy → Hold
Jul-24-23 Initiated Citigroup Buy
May-01-23 Initiated Truist Buy
Mar-28-23 Upgrade UBS Neutral → Buy
Jun-14-22 Initiated UBS Neutral
Mar-07-22 Downgrade JP Morgan Overweight → Neutral
Jul-16-20 Initiated BofA Securities Neutral
Apr-17-20 Initiated SunTrust Buy
Aug-13-19 Initiated Mizuho Buy
Aug-02-19 Reiterated H.C. Wainwright Buy
Aug-02-19 Reiterated Maxim Group Buy
Jun-11-19 Initiated Barclays Overweight
May-07-19 Initiated H.C. Wainwright Buy
Aug-28-18 Initiated H.C. Wainwright Buy
Mar-09-18 Reiterated Maxim Group Buy
Aug-08-17 Reiterated JP Morgan Overweight
Jun-13-17 Reiterated Maxim Group Buy
May-05-17 Initiated BMO Capital Markets Outperform
Oct-19-16 Initiated Robert W. Baird Outperform
Sep-07-16 Initiated Maxim Group Buy
Jul-27-16 Initiated Citigroup Buy
Jan-20-16 Initiated Credit Suisse Outperform
View All

Coherus Oncology Inc Stock (CHRS) Latest News

pulisher
Aug 18, 2025

Lobbying Update: $125,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative

Aug 18, 2025
pulisher
Aug 12, 2025

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 12, 2025
pulisher
Aug 11, 2025

Coherus Oncology’s Earnings Call Highlights Growth and Challenges - TipRanks

Aug 11, 2025
pulisher
Aug 10, 2025

Analysts' Revenue Estimates For Coherus Oncology, Inc. (NASDAQ:CHRS) Are Surging Higher - 富途牛牛

Aug 10, 2025
pulisher
Aug 10, 2025

Coherus Oncology's (CHRS) Strategic Reinvention: A High-Conviction Biotech Play for the Long Term - AInvest

Aug 10, 2025
pulisher
Aug 10, 2025

Industry Analysts Just Upgraded Their Coherus Oncology, Inc. (NASDAQ:CHRS) Revenue Forecasts By 21% - simplywall.st

Aug 10, 2025
pulisher
Aug 10, 2025

Need To Know: Analysts Are Much More Bullish On Coherus Oncology, Inc. (NASDAQ:CHRS) Revenues - Yahoo Finance

Aug 10, 2025
pulisher
Aug 08, 2025

Coherus Oncology 2025 Q2 Earnings Strong Turnaround with 2404.5% Net Income Surge - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Coherus Oncology shares rise 4.07% premarket after Q2 revenue up 36%. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips - Investing.com

Aug 08, 2025
pulisher
Aug 08, 2025

Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa

Aug 08, 2025
pulisher
Aug 08, 2025

Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Aug 08, 2025
pulisher
Aug 08, 2025

Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

Aug 08, 2025
pulisher
Aug 08, 2025

Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com

Aug 08, 2025
pulisher
Aug 08, 2025

Coherus Oncology Reports Strong Q2 2025 Growth - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 08, 2025
pulisher
Aug 07, 2025

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - 富途牛牛

Aug 07, 2025
pulisher
Aug 07, 2025

Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Coherus Oncology: Q2 Earnings Snapshot - San Antonio Express-News

Aug 07, 2025
pulisher
Aug 07, 2025

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times

Aug 07, 2025
pulisher
Aug 07, 2025

Coherus Oncology Q2 2025: LOQTORZI revenue up 36% to $10.0mln. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Coherus Oncology Reports Second Quarter 2025 Financial Results a - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

Coherus Oncology Reports 36% Increase in LOQTORZI Net Revenue for Q2 2025 and Updates on Pipeline Progress - Quiver Quantitative

Aug 07, 2025
pulisher
Aug 06, 2025

Insights Ahead: Coherus BioSciences's Quarterly Earnings - 富途牛牛

Aug 06, 2025
pulisher
Aug 06, 2025

Coherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by institutional shareholders who own 54% of the company - Yahoo Finance

Aug 06, 2025
pulisher
Aug 05, 2025

Coherus Oncology Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView

Aug 05, 2025
pulisher
Aug 03, 2025

What is Coherus BioSciences Inc. company’s growth strategyLightning-fast capital gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 01, 2025

Earnings Preview: CHRS to Report Financial Results Post-market on August 07 - 富途牛牛

Aug 01, 2025
pulisher
Jul 31, 2025

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 | CHRS Stock News - GuruFocus

Jul 31, 2025
pulisher
Jul 31, 2025

Coherus Oncology to Release Second Quarter 2025 Financial Results on August 7, 2025 - Quiver Quantitative

Jul 31, 2025
pulisher
Jul 31, 2025

Coherus Earnings: Q2 2025 Results and Management Call Set for August 7 After Market Close - Stock Titan

Jul 31, 2025
pulisher
Jul 26, 2025

Why Coherus BioSciences Inc. stock attracts strong analyst attentionHigh Reward Risk Balanced Trading - metal.it

Jul 26, 2025
pulisher
Jul 24, 2025

Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35% - simplywall.st

Jul 24, 2025
pulisher
Jul 14, 2025

Positive week for Coherus Oncology, Inc. (NASDAQ:CHRS) institutional investors who lost 47% over the past year - simplywall.st

Jul 14, 2025
pulisher
Jul 11, 2025

Alvotech: A Fast Expanding Biosimilar Concern (NASDAQ:ALVO) - Seeking Alpha

Jul 11, 2025
pulisher
Jul 09, 2025

Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Are Reducing Their Forecasts For This Year - 富途牛牛

Jul 09, 2025
pulisher
Jul 03, 2025

Coherus Biosciences Receives Nasdaq Deficiency Notice - TipRanks

Jul 03, 2025
pulisher
Jun 25, 2025

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? - Yahoo Finance

Jun 25, 2025
pulisher
Jun 13, 2025

Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Coherus Oncology reports annual meeting results - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Coherus Biosciences Holds Virtual Annual Stockholder Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 06, 2025

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey

Jun 06, 2025
pulisher
Jun 06, 2025

Coherus Oncology shares fall 1.20% after-hours following resignation of Chief Commercial Officer. - AInvest

Jun 06, 2025
pulisher
Jun 04, 2025

Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
May 31, 2025

Coherus BioSciences Renames to Coherus Oncology, Focusing on Cancer Treatments. - AInvest

May 31, 2025
pulisher
May 31, 2025

Genocea Biosciences (NASDAQ:GNCAQ) vs. Coherus BioSciences (NASDAQ:CHRS) Critical Survey - Defense World

May 31, 2025
pulisher
May 30, 2025

Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Coherus Biosciences Rebrands to Coherus Oncology - TipRanks

May 30, 2025
pulisher
May 30, 2025

Coherus Completes Strategic Transformation to Coherus Oncology, - GuruFocus

May 30, 2025

Coherus Oncology Inc Stock (CHRS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):